Global Leading Market Research Publisher QYResearch announces the release of its latest report “Bifidobacterium Animalis Subsp. Lactis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bifidobacterium Animalis Subsp. Lactis market, including market size, share, demand, industry development status, and forecasts for the next few years.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6092089/bifidobacterium-animalis-subsp--lactis

1. Market Overview: Addressing the Gut Health Imperative
Bifidobacterium animalis subsp. lactis is a strictly anaerobic Gram-positive probiotic widely recognized for digestive and immune health benefits. For consumers seeking gut microbiota regulation—parents of infants, health-conscious adults, and pet owners—this strain offers clinically validated support. However, downstream users face challenges: maintaining strain viability through shelf life, navigating complex regulations, and securing access to patented strains.

Core market data:
In 2025, the global market was valued at US$ 905 million, projected to reach US$ 1,705 million by 2032 at a CAGR of 9.6% .

Production & pricing metrics (2024):

Global production: 6,500 tons at US$ 2.30/kg

Freeze-dried powder capacity: 50–150 tons/line/year

Gross profit margin: 35–55%

2. Technical Deep Dive: Strain Activity, Acid Resistance & Fermentation
Keyword focus: Strain activity / Acid resistance / Fermentation processes / Bile salt resistance

Clinical efficacy depends on strain activity (viable CFU/g), acid resistance (survival through stomach pH 2–3), and bile salt resistance (survival through small intestine). Without these, probiotics fail to reach the gut alive.

Technical bottleneck – Maintaining viability:
Freeze-drying reduces viable counts by 50–70% without optimized protectants. Room-temperature storage degrades viability by 10–20% annually.

Recent development (last 6 months):
In January 2026, Novonesis announced a third-generation freeze-drying process for B. lactis BB-12® increasing viable count retention from 72% to 91% over 24 months, reducing cold chain costs by 30%.

独家观察 – Strain source segmentation:

Source Type Key Applications
Breast milk/infant intestinal Infant formula, baby foods
Intestinal (long-lived populations) Senior nutrition, anti-aging supplements
Special environmental sources Research, niche functional foods
3. Downstream Demand & Application Segmentation
Keyword focus: Infant formula / Probiotic solid beverages / Pet probiotic preparations / Medical food

Infant formula (~40% of market): China's GB 10765-2025 (effective December 2025) mandates probiotic supplementation for follow-up formulas, driving massive procurement. A single large manufacturer may use 500–1,000 tons annually.

Probiotic solid beverages (fastest-growing, ~30% CAGR): Single-serve sticks for convenient gut health. Brands like Wecare Probiotics lead this segment.

Pet probiotic preparations (emerging, ~25% CAGR): Functional treats for dogs and cats. Probiotical and Glac Biotech offer heat-stable formulations for extruded kibble.

Medical food companies (stable niche): Gut improvement programs for lactose-intolerant individuals.

Typical user case – Infant formula reformulation (Q4 2025):
A top-5 Chinese brand replaced its standard strain with a higher-bile-salt-resistant variant from Howaru . Results over 6 months:

Strain survival through simulated digestion increased from 18% to 47%

Clinical trial (n=300) showed 32% reduction in colic symptoms

Retail price increased 12% with no sales velocity impact

4. Industry Chain & Competitive Landscape
Upstream: Strain preservation institutions (DSMZ, ATCC), fermentation raw materials, freeze-drying protectants. Patent barriers are high—core strains like BB-12® (Novonesis) remain proprietary.

Key players: Novonesis, IFF, Lallemand, Wecare Probiotics, Scitop, Yili Group, Probiotical, Glac Biotech, Yuansheng Biotechnology, Howaru, BGI, Sacco System, Unique Biotech, Bio-Growing.

独家观察 – Regional dynamics:
China is both the largest consumer and a major producer. Yili Group and Yuansheng operate fermentation capacity exceeding 10,000 tons annually. However, Chinese manufacturers pay 8–12% royalties to Novonesis or IFF for licensed strains. Indigenous strain development is accelerating but requires 5–7 years for infant formula approval.

5. Policy Drivers, Challenges & Forecast
Policy driver – China GB 10765-2025 (effective December 2025):
Requires (1) viable count ≥10⁶ CFU/g at end of shelf life; (2) strain-level WGS identification; (3) clinical evidence per claim. Favors large suppliers with stability data.

Driving factors:

Increased consumer awareness of gut health

Stricter infant formula regulations

Booming pet probiotics (pet humanization trend)

Strengthening scientific evidence

Obstacles:

High patent barriers; core strains controlled by international companies

Stringent sterile environment and equipment requirements

Strict regulations on labeling and efficacy claims

3–5 year development timelines for new strain approval

Forecast (2026–2032):
The 9.6% CAGR will be driven by infant formula fortification mandates, pet probiotic premiumization, and novel strain development.

Strategic recommendations:

Invest in proprietary strain libraries – reduce royalty dependence

Document room-temperature stability – cold chain reduction is key

Develop pet-specific formulations – lower regulatory barriers, faster growth

Prepare for Codex Alimentarius harmonization (expected 2027–2028)

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp